Timing clarification: Alexandria is scheduled to release Q2 results after the market closes today, Monday, August 3, 2026. The earnings call is tomorrow, Tuesday, August 4, at 2:00 p.m. ET. (investor.are.com)
This report is less about whether ARE beats quarterly FFO by a few cents and more about whether management can demonstrate that its multiyear reset is working.
The central questions are:
Q2 itself will probably remain operationally weak. Significant lease expirations occurred during the first half, while much of the benefit from already-signed leases is not expected until later in 2026. Investors should therefore focus heavily on forward leasing, dispositions, occupancy timing, and the quality of guidance.
| Metric | Q2 expectation/reference |
|---|---|
| Third-party consensus per-share estimate* | $1.64 |
| Revenue consensus | $653.7 million |
| Q1 2026 adjusted FFO/share | $1.73 |
| Q2 2025 adjusted FFO/share | $2.33 |
| FY2026 adjusted FFO guidance | $6.30–$6.50 |
| FY2026 midpoint | $6.40 |
| Q1 operating occupancy | 87.7% |
| FY2026 year-end occupancy guide | 86.2%–87.8% |
| FY2026 same-property NOI guide | Down 10.5% to 8.5% |
| Q1 annualized leverage | 6.8x |
| Q4 leverage target | 5.6x–6.2x |
*Some data vendors label the $1.64 estimate as “EPS,” but their historical series matches ARE’s adjusted FFO-per-share results; investors should treat it primarily as an adjusted-FFO proxy. The same source expects revenue of approximately $653.7 million. (benzinga.com)
ARE maintained a $6.40 full-year adjusted FFO midpoint last quarter while narrowing the range to $6.30–$6.50. However, it reduced its occupancy, same-property NOI, rent-spread and capitalized-interest assumptions. (are.com)
ARE entered Q2 with a $2.9 billion midpoint target for 2026 dispositions and sales of partial interests, with an assumed weighted-average completion date in August. At the end of April, only about $151 million was completed or pending, although another $2.18 billion was identified and in process.
That makes this report a critical progress check. Management needs to provide more than assurances that buyer interest is healthy.
Investors should look for:
Positive outcome: Material closings or binding agreements, with pricing that validates ARE’s underlying asset values.
Negative outcome: Another quarter dominated by “identified and in process” transactions, particularly if the expected completion schedule moves into late 2026 or 2027.
ARE signed only 647,000 square feet of leases in Q1, including no leases with public biotech tenants—an unprecedented result according to management. On the Q1 call, management indicated that Q2 leasing could rebound to approximately 900,000 square feet, based on activity then underway.
That 900,000-square-foot marker is one of the cleanest tests in the report.
The headline volume is not enough, however. Investors should examine:
ARE has been broadening the potential tenant pool at several properties to include advanced-technology users. That can reduce required capital and bring space into service sooner, but generally at lower rents than full laboratory use. The strategy is economically sensible if it generates acceptable returns; it would be less reassuring if it merely masks persistent weakness in core life-science demand.
Q1 renewal and re-leasing rents declined:
One Watertown entertainment-studio lease had an outsized impact, but even excluding it, spreads remained negative. A meaningful sequential improvement would support the view that Q1 was unusually weak. Continued double-digit declines, especially alongside rising concessions and tenant-improvement allowances, would indicate that landlords still have limited pricing power.
Operating occupancy fell from 90.9% at year-end 2025 to 87.7% in Q1. ARE also had another 747,000 square feet of known 2026 expirations expected to become vacant, with roughly 45% previously expected during Q2.
At the same time, ARE had approximately 1.1 million square feet of vacant space already leased but not delivered, representing about $68 million of prospective annual rental revenue. The weighted-average delivery date was around September 2026.
That creates a timing mismatch:
Investors should distinguish among three drivers of any occupancy change:
The best result would be an unchanged or clearly defined occupancy trough, supported by firm delivery schedules for the 1.1 million square feet. An apparent improvement driven mainly by selling vacant buildings would be less valuable.
The existing $6.40 adjusted FFO midpoint remains mathematically achievable.
After Q1’s $1.73, ARE needs another $4.67 per share over the final three quarters. Management’s Q4 guidance midpoint is approximately $1.45, implying combined Q2 and Q3 adjusted FFO of roughly $3.22, or about $1.61 per quarter.
Thus, a Q2 result near the $1.64 consensus would generally fit the existing full-year bridge.
The more important questions are:
A maintained headline range accompanied by weaker occupancy, more tenant reserves or a lower Q4 run rate would still be a negative report.
ARE ended Q1 with:
Management targets Q4 leverage of 5.6x–6.2x, with the improvement heavily dependent on completing dispositions and retiring short-term borrowing.
In July, ARE locked in terms for a proposed $5 billion unsecured revolving facility, with an additional $1 billion accordion. The expected floating-rate margin at closing is 72.5 basis points, and the facility could extend to January 2032 with two six-month extensions. This is a meaningful liquidity positive, but the agreement remains subject to effectiveness conditions and does not replace the need to deleverage. (sec.gov)
The key distinction:
A large revolver gives ARE time and flexibility. It does not solve the economic problem if property proceeds are delayed or realized at unattractive values.
ARE capitalized approximately $70 million of interest in Q1 on an average real estate basis of about $6.86 billion. Management expects that capitalized basis to decline substantially as projects are delivered, paused, sold or reach decision milestones.
Important exposure includes:
When qualifying development activity stops, interest and certain other costs can no longer be capitalized and instead run through current earnings. That can reduce FFO even if the underlying cash interest burden is unchanged.
Investors should watch for:
A decisive sale or lower-cost alternative use may be economically positive despite a near-term accounting headwind. Indefinite evaluation would be less constructive.
ARE increased its 2026 allowance for tenant wind-downs from roughly $23 million to $25–$30 million, with approximately $6 million recognized in Q1.
Investors should look for:
The larger forward risk is 2027. ARE identified approximately 1.5 million square feet of 2027 expirations, representing $97.4 million of annual rental revenue, that could experience six to 24 months of downtime. Only about 36% of that space was in early negotiations or associated with identified prospects at the end of Q1.
The key question is not whether 2027 will contain downtime—it will—but whether the $97.4 million exposure has:
An increase would challenge the thesis that 2026 represents the operating trough.
Based on ARE’s July 31 close of approximately $51.47:
That valuation reflects considerable skepticism, but expectations are no longer as depressed as they were immediately after Q1. ARE has risen about 13% from its April 27 close and approximately 27% from the post-earnings April 28 close.
The stock does not need an immediate return to growth to work. It does need evidence that:
| Scenario | What the report would likely show |
|---|---|
| Bull case | Q2 leasing around or above 900,000 square feet; renewed public-biotech activity; better rent spreads; major disposition closings at credible pricing; stable guidance; unchanged Q4 exit rate; tangible progress on 2027 expirations. |
| Base case | Adjusted FFO near $1.64; occupancy declines again; leasing improves but remains concession-heavy; some disposition progress; $6.40 guidance midpoint maintained; management reiterates that operating improvement begins later in 2026. |
| Bear case | Dispositions slip or pricing disappoints; leasing misses the indicated level; tenant reserves rise; occupancy guidance falls; capitalized interest declines faster; Q4 FFO guidance is reduced; more 2027 space is expected to go vacant. |
The decisive metric is not Q2 FFO—it is execution on the capital plan.
A modest earnings beat would carry limited value if dispositions remain delayed, leverage stays elevated and the 2027 vacancy risk grows. Conversely, a weak-looking quarter could be received positively if ARE announces substantial asset-sale proceeds, credible pricing, improved leasing and a firm second-half occupancy recovery.
The strongest report would combine realized capital recycling, leasing near or above 900,000 square feet, stable guidance and no expansion of the 2027 risk bucket. Without those elements, the market is likely to continue treating ARE’s low multiple as a reflection of unresolved structural risk rather than a straightforward valuation opportunity.